Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;21(7):e70506.
doi: 10.1002/alz.70506.

Sex differences in modifiable dementia risk factors: Findings from the Rush Memory and Aging Project

Jissa Martin  1   2 , Emily Hannah Gordon  1   2   3 , Natasha Reid  1   2 , Ruth Eleanor Hubbard  1   2   3 , David Denston Ward  1   2
Affiliations

Sex differences in modifiable dementia risk factors: Findings from the Rush Memory and Aging Project

Jissa Martin et al. Alzheimers Dement. 2025 Jul.

Abstract

Introduction: We aimed to calculate population attributable fractions (PAFs) for incident dementia and examine sex differences in individuals with no cognitive impairment (NCI) or mild cognitive impairment (MCI).

Methods: Longitudinal data from the Rush University Memory and Aging Project (MAP) were analyzed. Cox proportional-hazards models were used to estimate covariate-adjusted hazard ratios for incident dementia and calculate weighted PAFs within each cognitive status/sex subgroup.

Results: The analytical sample comprised 1481 NCI (76.7% female) and 515 MCI (69.7% female) participants. Overall PAFs were similar for NCI (18.2%) and MCI (18.6%) subgroups, however, sex differences were evident. Males had higher PAFs than females in both NCI (42.5% vs. 25.1%) and MCI (51.5% vs. 12.4%), with differing risk factor profiles.

Discussion: These findings support the notion that dementia risk is modifiable after the onset of MCI and that the number of potentially preventable dementia cases may be higher in males than in females.

Highlights: The proportion of potentially preventable dementia cases was similar for no cognitive impairment (NCI) and mild cognitive impairment (MCI) individuals. For both cognitive states, a higher proportion of potentially preventable dementia cases was observed in males compared to females. The profiles of modifiable risk factors contributing to dementia differed between males and females. Lifestyle related risk factors were more prominent contributors to preventable dementia in males. Psychosocial risk factors, such as depression and social isolation, were important contributors in females.

Keywords: dementia; mild cognitive impairment; modifiable risk factors; population attributable fractions; sex differences.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to report. Author disclosures are available in the supporting information.

Figures

FIGURE 1
FIGURE 1
Flowchart of study participant selection. MAP, Memory and Aging Project.
FIGURE 2
FIGURE 2
PAFs for modifiable dementia risk factors in males and females with no cognitive impairment. Outer circles represent the prevalence of each risk factor with larger, darker circles denoting higher prevalence. Gray lines connecting each outer circle to its corresponding inner circle indicate the hazard ratio for dementia. Inner circles represent the individual PAF for each factor with size proportional to PAF magnitude. PAF, population attributable fraction.
FIGURE 3
FIGURE 3
PAFs for modifiable dementia risk factors in males and females with mild cognitive impairment. Outer circles represent the prevalence of each risk factor with larger, darker circles denoting higher prevalence. Gray lines connecting each outer circle to its corresponding inner circle indicate the hazard ratio for dementia. Inner circles represent the individual PAF for each factor with size proportional to PAF magnitude. PAF, population attributable fraction; TBI, traumatic brain injury.
See this image and copyright information in PMC

References

    1. Van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. New England Journal of Medicine. 2023;388:9‐21. - PubMed
    1. Budd Haeberlein S, Aisen P, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. The Journal of Prevention of Alzheimer's Disease. 2022;9:197‐210. - PubMed
    1. Dantas JM, Mutarelli A, Navalha DD, et al. Efficacy of anti‐amyloid‐ß monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta‐analysis. Neurological Sciences. 2024;45:2461‐2469. - PubMed
    1. Jeremic D, Navarro‐López JD, Jiménez‐Díaz L. Efficacy and safety of anti‐amyloid‐β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: a systematic review and interactive web app‐based meta‐analysis. Ageing Research Reviews. 2023;90:102012. - PubMed
    1. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancetstanding Commission. The Lancet. 2024;404:572‐628. - PubMed